Date: 23-Oct-2019

New Horizon develops technology partnership with Prenetics

hina's leading non-invasive colon cancer screening biotech company, New Horizon Health Limited, announced in a signing ceremony that it had entered into an exclusive agreement with Prenetics Limited, a leading genetics and digital health company in Asia and Europe. Under the terms of the agreement, New Horizon will provide a technical transfer to Prenetics for ColoClear. ColoClear, a non-invasive multi-target stool DNA test for colorectal cancer, has been specifically developed for individuals whom are of Asian ethnicity and have been validated through clinical studies to perform at 92% sensitivity in the detection of colon cancer.